Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.

F, Peyvandi; S, Cataland; M, Scully; P, Coppo; P, Knoebl; Hovinga JA, Kremer; A, Metjian; la Rubia J, de; K, Pavenski; Mi Edou J, Minkue; Winter H, De; F, Callewaert

doi:10.1182/bloodadvances.2020001834

Public

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.

Shared by NobleBlocks on Apr 1, 2021 • 12:00 AM UTC

Authors:

Peyvandi F

Cataland S

Scully M

Abstract

The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to increase statistical power for assessing treatment dif...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!